Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female ≥18 years of age and currently receiving amifampridine phosphate for LEMS.~2. Diagnosis of LEMS by antibody testing or electromyography (EMG).~3. Completion of anti-cancer treatment at least 3 months (90 days) prior to Screening.~4. If receiving peripherally acting cholinesterase inhibitors (e.g. pyridostigmine), a stable dose of cholinesterase inhibitors is required for at least 7 days prior to randomization and throughout the study.~5. If receiving permitted oral immunosuppressants (prednisone or other corticosteroid), a stable dose is required for at least 30 days prior to randomization and throughout the study.~6. Female patients of childbearing potential must practice an effective, reliable contraceptive regimen during the study.~7. Able to perform all study procedures and assessments.~8. Willing and able to travel to study site and attend all clinic study visits.~9. Willing and able to provide written informed consent.~Exclusion Criteria:~1. Clinically significant long corrected QT (QTc) interval on ECG in previous 12 months.~2. Seizure disorder.~3. Active brain metastases.~4. Unable to ambulate.~5. Pregnant or lactating females.~6. Any other condition which, in the opinion of the Investigator, might interfere with the patient's participation in the study or confound the assessment of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amifampridine phosphate (Type: EXPERIMENTAL): amifampridine phosphate 10 mg (amifampridine equivalent) by mouth, 30 to 80 mg total daily dose, 3 to 4 times per day for 4 days
- placebo (for amifampridine phosphate) (Type: PLACEBO_COMPARATOR): placebo by mouth 3 to 4 times per day for 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).